SCHEMBL1241307

SCHEMBL1241307

CN(C)CC(CO)c1ccc(Br)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 0.39
CHRM1 P11229 3/20 0.39
DRD1 P21728 3/20 0.39
SLC6A2 P23975 3/20 0.39
SLC6A4 P31645 3/20 0.39
SLC6A3 Q01959 3/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
TBXA2R P21731 1/20 0.39
OPRM1 P35372 1/20 0.39
DRD3 P35462 1/20 0.39
HRH1 P35367 3/20 0.39
KCNH2 Q12809 2/20 0.39
HRH3 Q9Y5N1 2/20 0.39
HTR2A P28223 2/20 0.39
LMNA P02545 1/20 0.39
CYP2D6 P10635 1/20 0.39
NFKB1 P19838 1/20 0.39
THPO P40225 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3028964 0.88 TAAR1 (0.43) CHRM2CHRM1DRD1SLC6A2SLC6A4
SCHEMBL16327095 0.82 CHRNA7 (0.43) SLC6A2SLC6A4SLC6A3HRH1HTR2A
SCHEMBL537267 0.81 CYP2A6 (0.42) SLC6A2SLC6A4SLC6A3HTR2ACYP1A2
SCHEMBL9807100 0.80 HTR2A (0.59) SLC6A2SLC6A4SLC6A3HRH1KCNH2
Bromide SCHEMBL8083319 0.78 HTR2A (0.57) SLC6A2SLC6A4SLC6A3HRH1KCNH2
SCHEMBL12891099 0.78 LMNA (0.42) SLC6A2SLC6A4SLC6A3KCNH2LMNA
SCHEMBL3857347 0.78 HDAC8 (0.44) CHRM2CHRM1DRD1SLC6A2SLC6A4
SCHEMBL8164326 0.78 HDAC8 (0.44) CHRM2CHRM1DRD1SLC6A2SLC6A4
SCHEMBL1239178 0.76 AOC3 (0.47) CHRM2CHRM1DRD1SLC6A2SLC6A4
SCHEMBL10915673 0.72 PYCR1 (0.44) CHRM2CHRM1DRD1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879808-B2 potent activity against resistant pneumococci; for treating domestic fowl MEIJI SEIKA KAISHA, LTD. (JP) 2011-02-01 US disclosed
US-20100210570-A1 LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2010-08-19 US disclosed
EP-2151447-A1 LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT Meiji Seika Kaisha Ltd. (JP) 2010-02-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210570-A1 LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT LAS1L, LCLAT1, LYPLA1 CHRM2 2320/4885CHRM1 620/4885DRD1 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.